New hope for myelofibrosis patients who failed standard therapy

NCT ID NCT07443306

Recruiting now Disease control Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study tests an experimental drug called flonoltinib maleate in about 64 people with a rare bone marrow cancer (myelofibrosis) that is moderate to high risk and has not responded to or stopped responding to standard JAK inhibitor therapy. Participants take a daily pill on an empty stomach. The main goal is to see if the drug can shrink the spleen by at least 35% and improve symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MF

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)
RECRUITING

Tianjin, Tianjin Municipality, China
West China Hospital Sichuan University
RECRUITING

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.